Works Cited
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.
1. Gregory TB. Chronic pain perspectives: Sickle cell disease: gaining control over the pain. J Fam Pract. 2012;61(9 Suppl):S5-S8.
2. Centers for Disease Control and Prevention. Sickle Cell Disease. Available at https://www.cdc.gov/sickle-cell/about/index.html/. Last accessed October 25, 2025.
3. Brawley OW, Cornelius LJ, Edwards LR, et al. National Institutes of Health Consensus Development Conference Statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148(12):932-938.
4. World Health Organization. Sickle-Cell Anaemia. Available at http://apps.who.int/gb/archive/pdf_files/WHA59/A59_9-en.pdf. Last accessed October 25, 2025.
5. Centers for Disease Control and Prevention. Sickle Cell Disease. What is Sickle Cell Trait? Available at https://www.cdc.gov/sickle-cell/sickle-cell-trait/index.html. Last accessed October 25, 2025.
6. McClish DK, Smith WR, Dahman BA, et al. Pain site frequency and location in sickle cell disease: the PiSCES project. Pain. 2009;145(1-2):246-251.
7. Hsieh MM, Fitzhugh CD, Tisdale JF. Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood. 2011;118(5):1197-1207.
8. Taylor LE, Stotts NA, Humphreys J, Treadwell MJ, Miaskowski C. A review of the literature on the multiple dimensions of chronic pain in adults with sickle cell disease. J Pain Symptom Manage. 2010;40(3):416-435.
9. National Heart, Lung, and Blood Institute. What Is Sickle Cell Disease? Available at https://www.nhlbi.nih.gov/health/sickle-cell-disease. Last accessed October 25, 2025.
10. LexiDrug. Available at https://online.lexi.com. Last accessed October 25, 2025.
11. National Heart, Lung, and Blood Institute. Sickle Cell Disease: Treatment. Available at https://www.nhlbi.nih.gov/health/sickle-cell-disease/treatment. Last accessed October 25, 2025.
12. U.S. Food and Drug Administration. FDA is Alerting Patients and Health Care Professionals About the Voluntary Withdrawal of Oxbryta From the Market Due to Safety Concerns. Available at https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerting-patients-and-health-care-professionals-about-voluntary-withdrawal-oxbryta-market-due#. Last accessed October 25, 2025.
13. Pfizer. Press Release. Pfizer Voluntary Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA (voxelotor) From Worldwide Markets. Available at https://www.pfizer.com/news/press-release/press-release-detail/pfizer-voluntarily-withdraws-all-lots-sickle-cell-disease. Last accessed October 25, 2025.
- Back to Course Home
- Participation Instructions
- Review the course material online or in print.
- Complete the course evaluation.
- Review your Transcript to view and print your Certificate of Completion. Your date of completion will be the date (Pacific Time) the course was electronically submitted for credit, with no exceptions. Partial credit is not available.